CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
This article was sponsored by AstraZeneca.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
September 3rd 2020
Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.
September 2nd 2020
An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.
August 29th 2020
Arzerra will be available at no cost to patients via an oncology patient access program which will be facilitated through Patient Access Novartis Oncology.
August 8th 2020
WellBe, a new voice-enabled virtual assistant, can remind patients with cancer to take their medication and keep them on track from the comfort of their own home.
August 5th 2020
Dr. Othman Al-Sawaf discusses the encouraging long-term data that makes the Venclexta-Gazyva combination a viable treatment option for patients with CLL.
August 5th 2020
“Final results from ASCEND confirm the findings of the interim analysis and support the favorable efficacy and safety of (Calquence) versus standard-of-care regimens in relapsed or refractory CLL,” said Dr. Paolo Ghia.
August 5th 2020
A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.
July 30th 2020
A list of the recent trial initiations that occurred within the cancer space in July.
July 21st 2020
A three-drug treatment sparked complete responses in more than half of patients with high-risk chronic lymphocytic leukemia, who also tolerated the regimen well.
July 2nd 2020
“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE®.
June 30th 2020
“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”
June 29th 2020
In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.
June 27th 2020
In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.
June 26th 2020
There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.
June 25th 2020
Here is a list of the recent trial initiations that occurred within the cancer space in June.
June 23rd 2020
Regulation changes could eliminate barriers to potentially lifesaving CAR-T cell immunotherapy for patients covered by Medicare or Medicaid.
June 19th 2020
From a study showing a popular cancer side effect management steroid decreasing the risk of death for patients in the hospital with COVID-19 to a new liquid biopsy test detecting lingering cancer in DNA, here’s what’s making the headlines in the cancer space this week.
June 8th 2020
Here is a roundup of the latest news and updates for patients with Chronic Lymphocytic Leukemia from CURE.
June 5th 2020
“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.
June 4th 2020
“Collectively, these results support acalabrutinib (Calquence) use in upfront CLL,” said Dr. John C. Byrd. “This is compounded and supported by two additional phase III studies that have been completed with this agent.”
June 3rd 2020
Results from an early-phase trial showed that cirmtuzumab plus Imbruvica is safe and efficacious in treating patients with relapsed/refractory MCL and CLL.
May 12th 2020
In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Dr. Farukh Awan addressed concerns about the possibility of developing COVID-19 or any infection after a stem cell transplant to treat a blood cancer.
May 7th 2020
In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Zainab Shahid, Farukh Awan and Ian Flinn addressed clinical trials that are underway to assess therapeutic approaches to COVID-19, including what role BTK inhibitors might play in treating the virus.
May 6th 2020
In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Lee Greenberger addresses steps that the Leukemia and Lymphoma Society have taken to help patients with blood cancer during the COVID-19 pandemic.
May 6th 2020
In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Ian Flinn and Farrukh Awan addressed what patients with blood cancers could do to help boost their immune systems to help prevent infections such as COVID-19, and the risk for patients who are several years removed from receiving a stem cell transplant.